Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025
Compass Therapeutics (NASDAQ: CMPX), a clinical-stage oncology biopharmaceutical company, will host its Q2 2025 financial results conference call on August 11, 2025, at 8:00 AM ET. The presentation will include updates on multiple programs including the tovecimig Phase 2/3 study, clinical data for CTX-8371, and preclinical data for CTX-10726.
Investors can access the webcast via the provided link or join by phone using the dial-in numbers. A replay will be available for 90 days on Compass' Events page.
Compass Therapeutics (NASDAQ: CMPX), una societ脿 biofarmaceutica oncologica in fase clinica, terr脿 la conference call sui risultati finanziari del secondo trimestre 2025 il 11 agosto 2025 alle 8:00 ET. La presentazione includer脿 aggiornamenti su pi霉 programmi, incluso lo studio di fase 2/3 di tovecimig, i dati clinici di CTX-8371 e i dati preclinici di CTX-10726.
Gli investitori potranno seguire il webcast tramite il link fornito o partecipare telefonicamente usando i numeri di accesso. Una registrazione sar脿 disponibile per 90 giorni nella pagina Eventi di Compass.
Compass Therapeutics (NASDAQ: CMPX), una compa帽铆a biofarmac茅utica oncol贸gica en fase cl铆nica, celebrar谩 su conferencia telef贸nica sobre resultados financieros del 2T 2025 el 11 de agosto de 2025 a las 8:00 ET. La presentaci贸n incluir谩 actualizaciones de varios programas, incluido el estudio de fase 2/3 de tovecimig, los datos cl铆nicos de CTX-8371 y los datos precl铆nicos de CTX-10726.
Los inversores podr谩n acceder al webcast mediante el enlace proporcionado o unirse por tel茅fono usando los n煤meros de marcaci贸n. Una grabaci贸n estar谩 disponible durante 90 d铆as en la p谩gina de Eventos de Compass.
Compass Therapeutics (NASDAQ: CMPX)電� 鞛勳儊 雼硠鞚� 膦呾枒頃� 氚旍澊鞓れ牅鞎� 須岇偓搿�, 2025雲� 2攵勱赴 鞁れ爜 旖橅嵓霟办姢 旖滌潉 2025雲� 8鞗� 11鞚� 鞓れ爠 8鞁�(ET)鞐� 臧滌禍頃╇媹雼�. 氚滍憸鞐愳劀電� tovecimig鞚� 2/3靸�(Phase 2/3) 鞐瓣惮, CTX-8371鞚� 鞛勳儊 雿办澊韯�, CTX-10726鞚� 鞝勳瀯靸� 雿办澊韯� 霌� 鞐煬 頂勲攴鸽灗鞐� 雽�頃� 鞐呺嵃鞚错姼臧� 韽暔霅╇媹雼�.
韴瀽鞛愲摛鞚� 鞝滉车霅� 毵來伂毳� 韱淀暣 鞗轨簮鞀ろ姼鞐� 鞝戩啀頃橁卑雮� 鞝勴檾 鞝戩啀 氩堩樃搿� 彀胳棳頃� 靾� 鞛堨姷雼堧嫟. 旖橅嵓霟办姢 旖� 雲轨潓鞚� Compass鞚� 鞚措菠韸� 韼橃澊歆�鞐愳劀 90鞚� 霃欖晥 雼れ嫓氤搓赴搿� 鞝滉车霅╇媹雼�.
Compass Therapeutics (NASDAQ: CMPX), une soci茅t茅 biopharmaceutique oncologique en phase clinique, tiendra sa conf茅rence t茅l茅phonique sur les r茅sultats financiers du T2 2025 le 11 ao没t 2025 脿 8h00 (ET). La pr茅sentation comprendra des mises 脿 jour sur plusieurs programmes, y compris l鈥�茅tude de phase 2/3 de tovecimig, les donn茅es cliniques de CTX鈥�8371 et les donn茅es pr茅cliniques de CTX鈥�10726.
Les investisseurs pourront acc茅der au webinaire via le lien fourni ou se joindre par t茅l茅phone en utilisant les num茅ros d鈥檃cc猫s. Une rediffusion sera disponible pendant 90 jours sur la page 脡v茅nements de Compass.
Compass Therapeutics (NASDAQ: CMPX), ein klinisch t盲tiges onkologisches Biopharmaunternehmen, wird seine Telefonkonferenz zu den Finanzergebnissen f眉r das zweite Quartal 2025 am 11. August 2025 um 8:00 Uhr ET abhalten. Die Pr盲sentation enth盲lt Updates zu mehreren Programmen, darunter die Phase鈥�2/3鈥慡tudie zu tovecimig, die klinischen Daten zu CTX鈥�8371 und die pr盲klinischen Daten zu CTX鈥�10726.
Investoren k枚nnen das Webcast 眉ber den bereitgestellten Link verfolgen oder sich telefonisch 眉ber die Einwahlnummern zuschalten. Eine Aufzeichnung wird f眉r 90 Tage auf der Eventseite von Compass verf眉gbar sein.
- None.
- None.
BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, will release its financial results for the quarter ended聽June 30, 2025 and host a webcast and conference call to provide an update on the ongoing tovecimig Phase 2/3 study, clinical data for CTX-8371 and preclinical data for CTX-10726, on聽Monday, August 11, 2025, at聽8:00 a.m. ET.
Call Details:
Date: Monday, August 11, 2025
Time: 8:00 AM ET
奥别产肠补蝉迟:听
Dial-In: 1-877-407-9716 (US), 1-201-493-6779 (International), 13754954 (Conference ID)
Virtual/Replay availability: A replay will be archived for 90 days on Compass鈥櫬犔璨共当�.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company鈥檚 scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The Company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at聽https://www.compasstherapeutics.com.
Investor Contact
[email protected]
Media Contact
Anna Gifford, Chief of Staff
[email protected]
617-500-8099
FAQ
When will Compass Therapeutics (CMPX) report Q2 2025 earnings?
What will be discussed in Compass Therapeutics' Q2 2025 earnings call?
How can investors access Compass Therapeutics' Q2 2025 earnings call?
How long will the replay of Compass Therapeutics' Q2 earnings call be available?
